# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop nex...
Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and lowers the price target from $195 to $187.